Here, we demonstrate that XPO1 inhibition enhances NK cell effector function against primary CLL cells via downregulation of HLA-E and upregulation of TRAIL death receptors DR4 and DR5. This evidence concerns the gene HLA-E and B-cell chronic lymphocytic leukemia.